Carl Icahn filed a complaint in Delaware against Amylin Pharmaceuticals (NASDAQ:AMLN) that seeks the extension of the board nomination deadline, and if successful, will nominate a slate of directors.The filing also demanded books and records to examine circumstances in relation to the reported Bristol-Myers Squibb (NYSE:BMY) proposal and stock offering.Amylin has until Wednesday to respond. Icahn intends on going to court if the firm doesn’t respond.This is news comes after Amylin rejected a $22 per share offer from Bristol-Myers earlier this year.
